Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13025755 | 0.97 | HCRTR1 (0.33) | HCRTR1HCRTR2CALM1GABRA1GABRB2 | |
| SCHEMBL14362915 | 0.89 | HCRTR1 (0.35) | HCRTR1HCRTR2CALM1GABRA1GABRB2 | |
| SCHEMBL13025769 | 0.86 | HCRTR1 (0.33) | HCRTR1HCRTR2GABRA1GABRB2 | |
| SCHEMBL13025837 | 0.85 | FFAR1 (0.34) | — | |
| SCHEMBL14362941 | 0.85 | GABRA1 (0.36) | HCRTR1HCRTR2CALM1GABRA1GABRB2 | |
| SCHEMBL13025668 | 0.85 | VEGFA (0.33) | HCRTR1HCRTR2CALM1GABRA1GABRB2 | |
| SCHEMBL13025747 | 0.82 | RXRA (0.34) | GABRA1GABRB2VEGFA | |
| SCHEMBL14362916 | 0.82 | PPARG (0.36) | — | |
| SCHEMBL13026090 | 0.82 | RXRA (0.35) | HCRTR1HCRTR2GABRA1GABRB2 | |
| SCHEMBL12834197 | 0.81 | CYP2C9 (0.34) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731493-B1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORP (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | HCRTR1 2214/4885HCRTR2 1589/4885CALM1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.